Bacil Pharma Limited appointed Mahesh Singh as an additional independent director and Anil Shiv Charan Singh as an additional non-executive director on August 25, 2026. The appointments require shareholder approval.

The board approved the appointments during a meeting held on Tuesday, August 25, 2026. Both directors have submitted necessary declarations under the Companies Act, 2013 and SEBI LODR Regulations. They are not debarred from holding office by any regulatory authority.

Director Profiles

Mahesh Singh brings over seven years of experience in the trading industry. His expertise includes product sales, brand establishment, and online sales strategies. The company cited his experience in accounting and financial matters as the reason for his appointment.

Anil Shiv Charan Singh has experience in business management and commercial activities. His background includes commodity trading and related business operations. The board noted his business acumen would contribute to strategic decision-making.

Regulatory Compliance

The appointments comply with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Detailed disclosures are enclosed in Annexure A of the filing. Neither director is related to any existing director of the company.

Bacil Pharma Limited has scheduled a meeting of its Board of Directors for Tuesday, August 25, 2026. The company disclosed the intimation pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015.

The board will consider key resolutions during the session. The primary agenda item involves the discussion on the appointment of directors. The meeting will also address any other business with the permission of the Chairperson.

The intimation was issued on August 17, 2026, by Ms. Chaitali Kalpataru Shah, Director & CFO of the company. She directed the communication to the Listing Department of BSE Limited for record-keeping purposes.

Agenda Details

The board meeting focuses on corporate governance updates rather than financial results. The specific items for consideration include:

• Discussion on the appointment of directors.
• Any other business permitted by the Chairperson.

No financial data, revenue figures, or profit metrics were disclosed in this filing, as it serves as a procedural notice for an upcoming governance event.